On August 26, 2020, dermavant Sciences announced that tapinarof (dmvt-505) (1% cream form), two multicenter, randomized, double-blind, blank matrix controlled phase 3 clinical trials for adult plaque psoriasis (plaque psoriasis) indications, named psoaring 1 and psoaring 2, have reached the primary endpoint.
Tapinarof is a therapeutic aromatics receptor modulator (Tama), which can be used to treat psoriasis and atopic dermatitis (AD). Tapinarof can regulate the activity of tyrosine kinase and aromatic hydrocarbon receptor, inhibit the production of inflammatory cytokines, infiltration of inflammatory cells, abnormal characterization of keratinocytes proliferation and angiogenesis and proliferation in psoriasis.
In July 2018, GSK announced that dermavant Sciences, a subsidiary of roivant Sciences, purchased the market ownership of tapinarof, a new psoriasis and atopic dermatitis drug under development, with a total cooperation amount of up to 250 million pounds. The initial cooperation payment is as high as 150 million pounds.
There are more than 6 million patients with psoriasis in China, and most of them are mild or moderate psoriasis. Psoriasis vulgaris accounts for more than 90%. Psoriasis patients suffer from itching, scaling and other symptoms for a long time, and bear the economic, psychological and other aspects of the disease burden. Domestic scholars have shown that 57% of patients with psoriasis are depressed and depressed and have a sense of inferiority. And psoriasis because it can not be cured, so recurrent attacks for a long time troubled patients, extending the remission period of treatment is also one of the primary treatment goals of dermatologists in the treatment of psoriasis. At present, topical drug treatment is suitable for the vast majority of patients with psoriasis, and it is the preferred treatment method, which is in the basic position in the treatment of psoriasis. However, the current external treatment still can not meet the clinical needs, such as treatment satisfaction is not high, repeated attacks and other issues. According to the enterprise side, benwimod, as the first external targeted immunomodulator, has definite curative effect better than the gold standard. After treatment, it can relieve symptoms for a long time, and the median remission period is as long as 9 months in the phase III clinical study.
NMPA/CDE/FDA；
Public disclosure of related companies;
http://www.stiefel.com/；
http://www.most.gov.cn/gnwkjdt/201907/t20190712_147685.htm；
https://www.dermavant.com/2018/07/；
<p style="margin: 0px 8px; padding: 0px; font-size: 17px; line-height: 1.5em; color: rgb(51, 51, 51); max-width: 100%; clear: both; min-height: 1em; font-family: -apple-system-font, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" letter-spacing:="" 0.544px;="" box-sizing:="" border-box="" !important;="" overflow-wrap:="" break-word="" !important;"="">https://www.dermavant.com/roivant-subsidiary-dermavant-sciences-signs-agreement-with-gsk-to-purchase-rights-to-tapinarof/；